Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission

Lisa Sproat, Brian Bolwell, Lisa Rybicki, Shawnda Tench, Josephine Chan, Matt Kalaycio, Robert Dean, Ronald Sobecks, Brad Pohlman, Steven Andresen, John Sweetenham, Edward Copelan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.

Original languageEnglish (US)
Pages (from-to)1699-1704
Number of pages6
JournalLeukemia and Lymphoma
Volume51
Issue number9
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Hematopoietic Stem Cells
Transplants
Drug Therapy
Cytogenetics
Mortality
Recurrence
Survival

Keywords

  • Acute myeloid leukemia
  • hematopoietic stem cell transplant
  • post-remission consolidation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. / Sproat, Lisa; Bolwell, Brian; Rybicki, Lisa; Tench, Shawnda; Chan, Josephine; Kalaycio, Matt; Dean, Robert; Sobecks, Ronald; Pohlman, Brad; Andresen, Steven; Sweetenham, John; Copelan, Edward.

In: Leukemia and Lymphoma, Vol. 51, No. 9, 09.2010, p. 1699-1704.

Research output: Contribution to journalArticle

Sproat, L, Bolwell, B, Rybicki, L, Tench, S, Chan, J, Kalaycio, M, Dean, R, Sobecks, R, Pohlman, B, Andresen, S, Sweetenham, J & Copelan, E 2010, 'Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission', Leukemia and Lymphoma, vol. 51, no. 9, pp. 1699-1704. https://doi.org/10.3109/10428194.2010.500431
Sproat, Lisa ; Bolwell, Brian ; Rybicki, Lisa ; Tench, Shawnda ; Chan, Josephine ; Kalaycio, Matt ; Dean, Robert ; Sobecks, Ronald ; Pohlman, Brad ; Andresen, Steven ; Sweetenham, John ; Copelan, Edward. / Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 9. pp. 1699-1704.
@article{8ad9da606c694b15b2f318543a627aa9,
title = "Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission",
abstract = "Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.",
keywords = "Acute myeloid leukemia, hematopoietic stem cell transplant, post-remission consolidation",
author = "Lisa Sproat and Brian Bolwell and Lisa Rybicki and Shawnda Tench and Josephine Chan and Matt Kalaycio and Robert Dean and Ronald Sobecks and Brad Pohlman and Steven Andresen and John Sweetenham and Edward Copelan",
year = "2010",
month = "9",
doi = "10.3109/10428194.2010.500431",
language = "English (US)",
volume = "51",
pages = "1699--1704",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission

AU - Sproat, Lisa

AU - Bolwell, Brian

AU - Rybicki, Lisa

AU - Tench, Shawnda

AU - Chan, Josephine

AU - Kalaycio, Matt

AU - Dean, Robert

AU - Sobecks, Ronald

AU - Pohlman, Brad

AU - Andresen, Steven

AU - Sweetenham, John

AU - Copelan, Edward

PY - 2010/9

Y1 - 2010/9

N2 - Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.

AB - Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.

KW - Acute myeloid leukemia

KW - hematopoietic stem cell transplant

KW - post-remission consolidation

UR - http://www.scopus.com/inward/record.url?scp=77956324597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956324597&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.500431

DO - 10.3109/10428194.2010.500431

M3 - Article

C2 - 20629524

AN - SCOPUS:77956324597

VL - 51

SP - 1699

EP - 1704

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -